James Lee on the vital role of business development for biotech companies

James Lee received his B.S and M.S. in Structural Biology from Seoul National University, he held various roles in research, research planning, and business development at LG Chem. In year 2000, James co-founded Crystal Genomics where he led fundraising and business development activities. In 2008, he founded Rexbio, an early-stage biotech startup specialized in discovering and developing therapeutics and diagnostics for the treatment of pancreatic cancer.

 

James founded Bridge Biotherapeutics Inc. in 2015 and he currently serves as the CEO. Bridge has been recognized with the continuous advancement of clinical-stage programs focused on pulmonary fibrosis, lung cancer, and immunology. In 2019, James successfully orchestrated the licensing-out deal with Boehringer Ingelheim, which marked as one of the largest global deals on a single compound in Korea.